MétaCan
Menu
Back to cohort
Record W4417080275 · doi:10.1016/j.xops.2025.101032

A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes

2025· article· en· W4417080275 on OpenAlexafffund
Mariella Saludares, Zachary Wennberg-Smith, Gala Beykin, Tasneem Khatib, Mariana Nuñez, Qianqian Wang, Adriana Di Polo, Jeffrey L. Goldberg

Bibliographic record

VenueOphthalmology Science · 2025
Typearticle
Languageen
FieldMedicine
TopicGlaucoma and retinal disorders
Canadian institutionsUniversité de Montréal
FundersNational Eye InstituteNational Institutes of HealthGlaucoma FoundationCanada Research ChairsFoundation Fighting BlindnessUniversité de MontréalResearch to Prevent BlindnessGlaucoma Research Foundation
KeywordsRandomized controlled trialInsulinPhase (matter)Diabetes mellitusMEDLINEClinical trial

Abstract

fetched live from OpenAlex

PURPOSE Insulin is neuroprotective in mouse and non-human primate models of glaucoma. Here we evaluate the safety and efficacy of topical insulin in human patients with glaucoma. METHODS This prospective study of once-daily topical insulin for glaucoma was conducted in two parts: an open-label dose escalation phase evaluating low (100 units/mL) and high doses (500 units/mL), followed by a randomized, masked trial comparing low and high dose topical insulin. The worse-affected eye served as the study eye while the contralateral eye served as a control. The primary endpoint was safety and tolerability, monitored by recording adverse events (AEs), intraocular pressure (IOP), and serum blood glucose and potassium levels. Secondary endpoints included structural and functional testing including visual acuity (VA), 24-2 Humphrey visual field (HVF), optical coherence tomography (OCT), and macular and peripapillary flavoprotein fluorescence (FPF). RESULTS Safety and tolerability were favorable for topical insulin at both doses, with no serious AEs. The most frequent AE was transient stinging, resolving almost immediately following application to the study eyes. Blood glucose levels remained consistently stable before and after insulin administration for all groups. In Group 3, five out of 15 study eyes showed an increase of average retinal nerve fiber layer (RNFL) thickness by 5 μm or more, compared to 0 of 12 fellow eyes from baseline to the 1-month visit (p=0.0476). On average, study eyes showed a larger increase in RNFL thickness compared to fellow eyes (1.11 μm in fellow eyes vs. 2.50 μm in study eyes) with no evidence of cystoid edema, and no difference detected between the two dose levels. The RNFL increase reversed to baseline by 1 month following cessation of insulin treatment. There were no changes in HVF or FPF during a 4-week administration period. CONCLUSIONS The application of topical insulin proved safe and well-tolerated among patients with glaucoma. Notably, one month of topical insulin led to a significant, reversible increase in RNFL thickness, indicating evidence for pharmacodynamic effect at the retina after topical delivery. These data support study initiation to evaluate topical insulin's neuroprotective or neuroenhancement effects.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.362
Teacher spread0.344 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueOphthalmology ScienceSame topicGlaucoma and retinal disordersFrench-language works237,207